| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514900900 | Follicle-stimulating hormone (FSH) or derivative | 27 |
| 20100249026 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 09-30-2010 |
| 20100261649 | LH LIQUID FORMULATIONS - The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration. | 10-14-2010 |
| 20110105398 | RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SAILYLATIO - Preparations including recombinant FSH (rFSH). | 05-05-2011 |
| 20110201554 | HFSH AQUEOUS FORMULATION - Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time. | 08-18-2011 |
| 20110218147 | ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation. | 09-08-2011 |
| 20110275567 | AQUEOUS COMPOSITION CONTAINING FOLLICLE-STIMULATING HORMONE - A stable aqueous composition containing follicle-stimulating hormone, which comprises follicle-stimulating hormone and histidine as a stabilizing agent. | 11-10-2011 |
| 20120015879 | Unitary combinations of FSH and hCG - A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration. | 01-19-2012 |
| 20120021984 | Glycoprotein Hormone Analogs - This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region. | 01-26-2012 |
| 20120021985 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 01-26-2012 |
| 20120035109 | FOLLICLE STIMULATING HORMONE SUPERAGONISTS - This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 02-09-2012 |
| 20120046228 | Methods for Modulating Ovulation - The present invention relates to methods and reagents for modulating ovulation in humans and non-human animals. | 02-23-2012 |
| 20120135928 | METHOD FOR PURIFYING RECOMBINANT FSH - The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or re-combinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies. | 05-31-2012 |
| 20120309681 | Treating or ameliorating some neuroendocrine disorders in male with help of prolactin - Methods, compositions and kits for treating or ameliorating the following disorders, in male, with help of prolactin are disclosed: a) erectile dysfunction (ED), also from aging, of pituitary/hypothalamic origin; b) premature ejaculation (PE), of pituitary/hypothalamic origin. Said methods, compositions and kits comprise prolactin, variants, analogs, agonists and functional fragments of prolactin, also in combination with conventional therapies and drugs (eg testosterone/androgens and/or gonadotropins). | 12-06-2012 |
| 20130023476 | Pharmaceutical Preparation Comprising Recombinant HCG - Preparations including recombinant hCG (r hCG). | 01-24-2013 |
| 20130137636 | RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE - The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment. | 05-30-2013 |
| 20130210727 | STABILIZATION OF FSH - The present invention, pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts. | 08-15-2013 |
| 20130237479 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION - A product comprising follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) for the treatment of infertility. | 09-12-2013 |
| 20140024589 | Follicle Stimulating Hormone Superagonists - Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders. | 01-23-2014 |
| 20140088010 | PHARMACEUTICAL PREPARATION - Preparations including poly (ethylene glycol) modified recombinant hCG(rhCG). | 03-27-2014 |
| 20140235540 | ANDROGEN AND GONADOTROPIN TREATMENT IN FEMALES - A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and/or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation. | 08-21-2014 |
| 20140329748 | Composition for Controlled Ovarian Stimulation - Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility. | 11-06-2014 |
| 20140349934 | METHOD FOR INDUCING TWIN CALVING - The present invention provides a method for inducing twin calving. The method according to the present invention comprises firstly treatment to inducing atresia of the antral follicles on ovary so as to initiate the development of new follicular wave, inducing the development of codominant follicles and further achieving double ovulations by exactly controlling the dosage and time points of hormone injections, and performing artificial insemination to induce the cow to deliver twin calves. The method according to the present invention has relative independent on the technical skills, and a person skilled in the art or a common worker can practice it according to specified operation methods; and during practical application, it does not require special equipment, thus saving cost, as well as improving the social benefit and economic benefit of cow breeding. | 11-27-2014 |
| 20150335713 | SINGLE DOSE RECOMBINANT BOVINE FSH AFTER FOLLICULAR SYNCHRONISATION - The present invention relates to methods and compositions for increasing reproduction performance in non-human mammals using a biologically active recombinant Follicle Stimulating Hormone (rFSH). The invention also relates to methods for increasing ovulation or embryo production or pregnancies in non-human mammal using rFSH. The invention may be used in particular in ungulates such as bovine or equine. | 11-26-2015 |
| 20150353599 | METHOD FOR PURIFYING RECOMBINANT FSH - The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies. | 12-10-2015 |
| 20150353886 | SALIVARY ESTRADIOL DETECTION METHODS AND USES FOR MONITORING OVULATION AND FERTILITY, AND SELECTION OR TIMING OF EGG RETRIEVAL AND/OR FERTILIZATION - This invention relates to methods to predict and monitor ovulation and fertility in female mammals by measuring the level of free salivary estradiol. Such information may be used to identify the appropriate timing for egg retrieval prior to in vitro fertilization (IVF), insemination procedures, natural or otherwise, and the timing for transfer of embryos. The ability to monitor salivary estradiol levels throughout the estrous cycle, with the optional application of an algorithm, will aid in identifying the peak time of fertility. | 12-10-2015 |
| 20160075751 | Glycoprotein Hormone Long-Acting Superagonists - This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 03-17-2016 |
| 20160250295 | FORMULATION FOR GONADOTROPINS | 09-01-2016 |
